TR200201724T2 - Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller - Google Patents

Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller

Info

Publication number
TR200201724T2
TR200201724T2 TR2002/01724T TR200201724T TR200201724T2 TR 200201724 T2 TR200201724 T2 TR 200201724T2 TR 2002/01724 T TR2002/01724 T TR 2002/01724T TR 200201724 T TR200201724 T TR 200201724T TR 200201724 T2 TR200201724 T2 TR 200201724T2
Authority
TR
Turkey
Prior art keywords
antihypertension
formulas
treat
methods
melatonin
Prior art date
Application number
TR2002/01724T
Other languages
English (en)
Inventor
Zisapel Nava
Laudon Moshe
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of TR200201724T2 publication Critical patent/TR200201724T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Bu bulus sözü geçen amaçlar, en azindan hastalik, sulandirici maddeler veya ek maddelerden birini içeren kimyasal formülleri saglayarak basariya ulasmis olabilir. Bir miktar melatonin, melatonin eksikligi görülen antihipertansiyon bilesimlerinde antihipertansiyon etkilere karsi dirençli hastalarin iyilestirilmesinde veya hipertansiyonu olusturan semptomlardan korumak için etkilidir; ve en azindan melatonin içerisindeki bir miktar gayret gösterecek antihipertansiyonun içerisinde bulunan antihipertansiyon bilesimi böyle bir tedavi için gereklidir.
TR2002/01724T 2000-01-05 2000-01-05 Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller TR200201724T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000009 WO2001049286A1 (en) 2000-01-05 2000-01-05 Method and formulation for treating resistance to antihypertensives and related conditions

Publications (1)

Publication Number Publication Date
TR200201724T2 true TR200201724T2 (tr) 2003-03-21

Family

ID=11042938

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01724T TR200201724T2 (tr) 2000-01-05 2000-01-05 Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller

Country Status (31)

Country Link
US (3) US7332177B1 (tr)
EP (1) EP1272177B1 (tr)
JP (1) JP4996803B2 (tr)
CN (1) CN1414851A (tr)
AT (1) ATE359072T1 (tr)
AU (1) AU782266B2 (tr)
BG (1) BG65637B1 (tr)
BR (1) BR0016918A (tr)
CA (1) CA2396129C (tr)
CY (2) CY1108018T1 (tr)
CZ (1) CZ299931B6 (tr)
DE (1) DE60034373T2 (tr)
DK (1) DK1272177T3 (tr)
EA (1) EA004679B1 (tr)
EE (1) EE200200379A (tr)
ES (1) ES2284471T3 (tr)
HK (1) HK1052655A1 (tr)
HU (1) HU227002B1 (tr)
IL (1) IL150190A0 (tr)
IS (1) IS6439A (tr)
MX (1) MXPA02005783A (tr)
NO (1) NO322567B1 (tr)
NZ (1) NZ520078A (tr)
PL (1) PL201219B1 (tr)
PT (1) PT1272177E (tr)
SI (1) SI1272177T1 (tr)
SK (1) SK287508B6 (tr)
TR (1) TR200201724T2 (tr)
TW (1) TWI260983B (tr)
UA (1) UA77394C2 (tr)
WO (1) WO2001049286A1 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US20050020666A1 (en) * 2003-07-25 2005-01-27 Dabur Research Foundation Cardioprotective agents
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
CA2815491C (en) * 2010-10-25 2015-12-15 Uico, Inc. Control system with solid state touch sensor for complex surface geometry
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US20190216336A1 (en) * 2016-08-18 2019-07-18 Koninklijke Philips N.V. Blood-pressure management
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
ES2724933A1 (es) * 2018-03-13 2019-09-17 Ocupharm Diagnostics Sl Terapia combinada con melatonina para la reducción de la presión intraocular
GB2617102A (en) * 2022-03-29 2023-10-04 John Hemming Trading Ltd Sleep therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
JPH07503232A (ja) * 1991-10-18 1995-04-06 アルザ・コーポレーション メラトニンの制御経皮投与
US5646049A (en) * 1992-03-27 1997-07-08 Abbott Laboratories Scheduling operation of an automated analytical system
EP0565296B1 (en) * 1992-04-07 1996-08-07 Neurim Pharmaceuticals (1991) Limited Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
WO1995002068A1 (fr) * 1993-07-09 1995-01-19 Wakunaga Seiyaku Kabushiki Kaisha Methode de discrimination des acides nucleiques et necessaire d'essai a cette fin
EE03384B1 (et) 1995-02-01 2001-04-16 Neurim Pharmaceuticals (1991) Ltd. Melatoniini kasutamine ravimi tootmiseks
US5648727A (en) * 1995-10-24 1997-07-15 Dpc Cirrus Inc. Capacitive level sensing pipette probe
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии

Also Published As

Publication number Publication date
US7332177B1 (en) 2008-02-19
US8075914B2 (en) 2011-12-13
NO20023102D0 (no) 2002-06-27
BR0016918A (pt) 2004-03-23
CY2007033I2 (el) 2009-11-04
BG106978A (en) 2003-03-31
US20080085317A1 (en) 2008-04-10
CZ20022346A3 (cs) 2002-11-13
IS6439A (is) 2002-06-24
MXPA02005783A (es) 2003-10-14
CY2007033I1 (el) 2009-11-04
EA200200738A1 (ru) 2002-12-26
NO20023102L (no) 2002-08-30
ATE359072T1 (de) 2007-05-15
HK1052655A1 (zh) 2003-09-26
CN1414851A (zh) 2003-04-30
PL201219B1 (pl) 2009-03-31
EP1272177B1 (en) 2007-04-11
ES2284471T3 (es) 2007-11-16
NZ520078A (en) 2004-02-27
SK9732002A3 (en) 2002-11-06
PT1272177E (pt) 2007-07-11
CY1108018T1 (el) 2011-04-06
CA2396129C (en) 2010-11-30
US20120070501A1 (en) 2012-03-22
DK1272177T3 (da) 2007-08-06
BG65637B1 (bg) 2009-04-30
AU1888200A (en) 2001-07-16
EP1272177A4 (en) 2004-04-28
HUP0204089A2 (hu) 2003-04-28
DE60034373T2 (de) 2007-12-20
EA004679B1 (ru) 2004-06-24
CZ299931B6 (cs) 2008-12-29
HUP0204089A3 (en) 2005-12-28
JP2003519181A (ja) 2003-06-17
UA77394C2 (uk) 2006-12-15
TWI260983B (en) 2006-09-01
EE200200379A (et) 2003-10-15
SI1272177T1 (sl) 2007-10-31
EP1272177A1 (en) 2003-01-08
IL150190A0 (en) 2002-12-01
AU782266B2 (en) 2005-07-14
WO2001049286A1 (en) 2001-07-12
CA2396129A1 (en) 2001-07-12
DE60034373D1 (de) 2007-05-24
HU227002B1 (en) 2010-04-28
US8728511B2 (en) 2014-05-20
NO322567B1 (no) 2006-10-30
SK287508B6 (sk) 2010-12-07
JP4996803B2 (ja) 2012-08-08
PL356325A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
TR200201724T2 (tr) Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
HK1085511A1 (en) Complement inhibitors from ticks
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE60112611T2 (de) Makroheterocyclische verbindungen als kinase inhibitoren
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
TW200510397A (en) Conjugated complement cascade inhibitors
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DK1231910T3 (da) Pentamidin til behandling af cancer
NO20051681L (no) Lysaldring av hud og aktinskadebehandling
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE346040T1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE60230641D1 (de) Lentivirale vektoren zur behandlung von schmerzen
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung